Israel’s NasVax has announced success in the Phase IIa clinical trial of its oral anti-CD3 antibody for treating hepatitis C, a chronic disease, which disrupts the functioning of the immune system. The treatment also worked on patients who don’t respond to interferon – the current medication.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000787396&fid=1725